Loading company…
Tianchen Biological develops macromolecular antibodies for autoimmune diseases and provides antibody testing services.
Tianchen Biological researches and develops differentiated macromolecular antibodies for autoimmune diseases, with pipelines for ophthalmology, nephrology and hematology. Its platforms cover antibody discovery, engineering and process development, and it also provides antibody testing. Based in Changshu, China, it raised Series C funding in June 2025, co-led by HighLight Capital and Qiming Venture Partners, with participation from other named investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in